Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2022, specifically reporting transaction notifications dated October 10, 2022, and filed on October 12, 2022. The document details share acquisitions by Principal Disclosing Market Participants (PDMRs) under the company's Performance Share Plan.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It strictly reports specific equity transactions.
- Instrument: Ordinary shares of 31 1/4 pence each (ISIN: GB00BN7SWP63).
- Transaction Price: £13.2260 per share.
- Total Volume Reported: 9,880.352 shares (aggregate of two transactions).
Material Changes
The filing reports no material changes to the company's financial position or operations. It documents routine share acquisitions resulting from dividend reinvestment for executive compensation plans.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this specific filing. The transactions were executed on the London Stock Exchange (XLON) and are subject to a 2-year holding period under the Performance Share Plan.
Important Facts for Investors
- Executive Acquisitions: CEO Emma Walmsley acquired 7,963.086 shares, and CFO Ian Mackay acquired 1,917.266 shares.
- Transaction Nature: Both acquisitions were automatic reinvestments of dividends paid on October 6, 2022, not open-market purchases with discretionary capital.
- Lock-up Period: The acquired shares are subject to a mandatory 2-year holding period.
- Market Data: The transactions occurred at a price of £13.2260 on the London Stock Exchange.